Androgen receptor-dependent and independent atheroprotection by testosterone in male mice

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5428-5437

  Bourghardt, Johan ^a   Wilhelmson, Anna S K ^a   Alexanderson, Camilla ^a   De Gendt, Karel ^b   Verhoeven, Guido ^b   Krettek, Alexandra ^c   Ohlsson, Claes ^d   Tivesten, Åsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; GAMMA INTERFERON; MESSENGER RNA; PLACEBO; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LIPID;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; AORTA; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; LIPID DIET; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUBERTY; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; AORTA DISEASE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; NONPARAMETRIC TEST; ORCHIECTOMY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CYTOKINES; LIPIDS; MALE; MICE; MICE, KNOCKOUT; ORCHIECTOMY; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 78049516208     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0663     Document Type: Article

References (39)

1. Wu FC, von Eckardstein A 2003 Androgens and coronary artery disease. Endocr Rev 24:183-217
2. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. Endocr Rev 24:313-340
3. Kaufman JM, Vermeulen A 2005 The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833-876
4. Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J, Lönn L, Orwoll E, Smith U, Labrie F, Ljunggren O, Tivesten A, Ohlsson C 2007 Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 92:4130-4137
5. Tivesten A, Mellström D, Jutberger H, Fagerberg B, Lernfelt B, Orwoll E, Karlsson MK, Ljunggren O, Ohlsson C 2007 Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS study in Sweden. J Am Coll Cardiol 50:1070-1076
6. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT 2004 Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109:2074-2079
7. Mäkinen J, Järvisalo MJ, Pöllänen P, Perheentupa A, Irjala K, Koskenvuo M, Mäkinen J, Huhtaniemi I, Raitakari OT 2005 Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45:1603-1608
8. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C 2009 Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482-2488
9. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N 2007 Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116:2694-2701
10. Laughlin GA, Barrett-Connor E, Bergstrom J 2008 Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68-75
11. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, Flicker L, Hankey GJ 2009 Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 94:2353-2359
12. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fiévet C, Faye JC, Bayard F 1997 17β-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17: 2679-2684
13. McRobb L, Handelsman DJ, Heather AK 2009 Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology 150: 841-848
14. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G 2001 Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 98:3589-3593
15. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K 1993 Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99:79-86
16. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl FW, Haasis R, Hanke H 1997 Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17:2192-2199
17. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 84:813-819
18. Li S, Li X, Li Y 2008 Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol 49:14-18
19. Jones TH, Saad F 2009 The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207:318-327
20. Nettleship JE, Jones TH, Channer KS, Jones RD 2007 Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfmmouse: an effect that is independent of the classic androgen receptor. Circulation 116:2427-2434
21. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, Devos A, Tan K, Atanassova N, Claessens F, Lécureuil C, Heyns W, Carmeliet P, Guillou F, Sharpe RM, Verhoeven G 2004 A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci USA 101: 1327-1332
22. Lallemand Y, Luria V, Haffner-Krausz R, Lonai P 1998 Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase. Transgenic Res 7:105-112
23. Purcell-Huynh DA, Farese Jr RV, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG 1995 Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 95:2246-2257
24. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) Method. Methods 25:402-408
25. Wang RS, Yeh S, Tzeng CR, Chang C 2009 Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr Rev 30:119-132
26. Hodgin JB, Maeda N 2002 Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 143:4495-4501
27. Movérare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, Vanderschueren D, Oscarsson J, Gustafsson JA, Ohlsson C 2006 Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity 14:662-672
28. Ignatenko LL, Mataradze GD, Rozen VB 1992 Endocrine mechanisms for the formation of sex-related differences in hepatic estrogen receptor content and their significance for the realization of an estrogen effect on angiotensinogen blood level in rats. Hepatology 15:1092-1098
29. Harada N, Yamada K 1992 Ontogeny of aromatase messenger ribonucleic acid in mouse brain: fluorometrical quantitation by polymerase chain reaction. Endocrinology 131:2306-2312
30. Phillips GB 2005 Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 90:2708-2711
31. Van Loo PL, Mol JA, Koolhaas JM, Van Zutphen BF, Baumans V 2001 Modulation of aggression in male mice: influence of group size and cage size. Physiol Behav 72:675-683
32. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S 2003 Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300:167-171
33. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H 2005 Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54:1000-1008
34. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C 2005 Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 54:1717-1725
35. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT 2008 Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama 299:39-52
36. Gillatt D 2006 Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 132(Suppl 1):S17-S26
37. Daskivich TJ, Oh WK 2006 Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 16:173-178
38. Taylor LG, Canfield SE, Du XL 2009 Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388-2399
39. Bhasin S, Jasuja R 2009 Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232-240